Prospective Clinical and Biologic Study of Secondary Cutaneous Effects in Targeted Cancer Therapies

The aim of the study is to do a descriptive analysis of the cutaneous toxicity observed in patients treated using targeted therapies in order to have a better understanding of the skin pathophysiology.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Gustave Roussy Cancer Campus Grand Paris

Villejuif, Val de Marne, 94805, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with cancer beginning a targeted therapy
Patients able to follow the protocol
Age >/= 18 years old
Signed inform consent

Exclusion criteria

Patient unable to follow the protocol, having a non cooperative behavior or unable to come to follow up visits or unable to complete the study
Pregnant or breastfeeding woman

Treatment and study plan

Biopsy

Procedure

Primary outcomes

Number of clinical secondary effects bind to targeted therapies

Time frame: Every 28 days up to 5 years

Dermatological exam including questionnaire, clinical examination and photographies

Sponsors and collaborators

Lead sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Other

Registry information

Acronym: SKINTARGET

Important dates

Study start: 2011
Primary completion: 2022
Study completion: 2022
First posted: Aug 7, 2015
Registry last updated: Mar 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed